Evaluation of the Treatment of Candiduria at an Academic Medical Center
- PMID: 26938759
- DOI: 10.1097/MJT.0000000000000021
Evaluation of the Treatment of Candiduria at an Academic Medical Center
Abstract
To evaluate the epidemiology, management, and outcomes associated with candiduria in intensive care unit (ICU) and medical ward (MW) patients. This was a retrospective cohort study conducted in a tertiary care academic medical center. Adult patients aged between 18 and 75 years who were admitted for at least 5 days with a urinary culture that grew a Candida species between July 2010 and June 2011 were included. Medical records were retrospectively reviewed. Laboratory data, urinary symptoms, risk factors for urinary and invasive candidiasis, treatment, and patient outcomes were collected and evaluated. Sixty-seven ICU and 65 MW patients met the inclusion criteria. ICU patients were more likely to have risk factors for invasive candidiasis and candiduria. Candida albicans and Candida glabrata were the most frequently identified urinary isolates. Antifungal therapy was commonly initiated despite rapid replacement or removal of urinary drainage devices and a lack of patient reported symptoms. Fluconazole was the most commonly used antifungal agent, followed by micafungin. Hospital length of stay did not vary significantly between the ICU and MW groups (P = 0.0628). All-cause mortality was higher in the ICU patients compared with that of the MW patients (22.4% vs. 3.1%, P = 0.0012). Differences exist between ICU and MW patients that develop candiduria with respect to risk factors, and outcomes. Antifungals, including fluconazole and micafungin, were often used inappropriately (ie, asymptomatic patients) in this patient cohort. Efforts to improve healthcare provider awareness of the contemporary recommendations to manage candiduria are necessary to improve patient care and antifungal use.
Similar articles
-
Micafungin treatment and eradication of candiduria among hospitalized patients.Int Urol Nephrol. 2016 Nov;48(11):1881-1885. doi: 10.1007/s11255-016-1410-0. Epub 2016 Sep 1. Int Urol Nephrol. 2016. PMID: 27587066
-
Catheter-associated candiduria: Risk factors, medical interventions, and antifungal susceptibility.Am J Infect Control. 2015 Jul 1;43(7):e19-22. doi: 10.1016/j.ajic.2015.03.013. Epub 2015 Apr 24. Am J Infect Control. 2015. PMID: 25920705
-
Risk factors for fluconazole-resistant invasive candidiasis in intensive care unit patients: An analysis from the China Survey of Candidiasis study.J Crit Care. 2015 Aug;30(4):862.e1-5. doi: 10.1016/j.jcrc.2015.04.002. Epub 2015 Apr 16. J Crit Care. 2015. PMID: 26002430
-
To treat or not to treat--critically ill patients with candiduria.Mycoses. 2008 Sep;51 Suppl 2:12-24. doi: 10.1111/j.1439-0507.2008.01570.x. Mycoses. 2008. PMID: 18721329 Review.
-
Candida urinary tract infections: treatment options.Expert Rev Anti Infect Ther. 2007 Apr;5(2):277-84. doi: 10.1586/14787210.5.2.277. Expert Rev Anti Infect Ther. 2007. PMID: 17402842 Review.
Cited by
-
Repeated antifungal use audits are essential for selecting the targets for intervention in antifungal stewardship.Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1993-2000. doi: 10.1007/s10096-018-3335-2. Epub 2018 Aug 4. Eur J Clin Microbiol Infect Dis. 2018. PMID: 30078143
-
Templated microbiology comments with candiduria to enhance antimicrobial stewardship.Antimicrob Steward Healthc Epidemiol. 2022 Sep 14;2(1):e156. doi: 10.1017/ash.2022.292. eCollection 2022. Antimicrob Steward Healthc Epidemiol. 2022. PMID: 36483356 Free PMC article.
-
Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: a Multi-institutional Study.Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01464-17. doi: 10.1128/AAC.01464-17. Print 2018 Jan. Antimicrob Agents Chemother. 2017. PMID: 29109159 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous